Skip to main content
OpenTrials
Completed

NCT Number: NCT00637052

A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia

This is a 2-phase study during which patients with select myeloid leukemias or advanced myelodysplastic syndrome (MDS), who have failed, refused or are not eligible for standard treatment, will receive investigational study drug ARRY-520.

The study has 3 parts. The first phase of the study, Phase 1, has 2 parts. In the first part of Phase 1, patients with select myeloid leukemias or advanced MDS will receive increasing doses of study drug on different schedules in order to achieve the highest dose possible that will not cause unacceptable side effects. Approximately 30 patients (per schedule) from the US will be enrolled in Part 1 (Completed). In the second part of Phase 1, patients with advanced MDS will receive the best dose of study drug and schedule determined from the first part of the study. Approximately 10 patients from the US will be enrolled in Part 2 (Completed).

In the third part of the study, Phase 2, patients with acute myeloid leukemia (AML) or advanced MDS will receive the best dose of study drug and schedule determined from the first part of the study and will be followed to see what side effects the study drug causes and to see what effectiveness it has, if any, in treating the cancer. Approximately 40 patients from the US will be enrolled in Part 3 (Withdrawn).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Advanced MDS Acute Myeloid Leukemia Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms Neoplasms by Histologic Type Precancerous Conditions Preleukemia

Age range

17 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Emory University School of Medicine, Winship Cancer Center, Atlanta, Georgia, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria (Part 2):

  • Patients with either Intermediate-2 or High risk MDS or with AML (>20% bone marrow blasts) with stable low or normal white blood cell count (WBC). Patients should have failed one prior chemotherapy regimen which should have included a hypomethylating agent.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2.
  • Discontinuation of prior treatment at least 2 weeks prior to the start of the study.
  • Adequate hepatic and renal function.
  • Additional criteria exist.

Key Exclusion Criteria (Part 2):

  • Concurrent cytotoxic therapy, or biological, endocrine and immunological response modifiers.
  • Previous radiation to >25% of bone marrow.
  • Other active malignancies.
  • Known positive serology for the human immunodeficiency virus (HIV).
  • Central nervous system involvement as documented by spinal fluid cytology.
  • Active, uncontrolled infection.
  • Additional criteria exist

Treatment and study plan

ARRY-520, KSP(Eg5) inhibitor; intravenous

Drug

Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.

Primary outcomes

  1. Establish the maximum tolerated dose (MTD) of the study drug.

    Time frame: Part 1

  2. Characterize the pharmacokinetics (PK) of the study drug.

    Time frame: Part 1

  3. Characterize the safety profile of the study drug in terms of adverse events, dose limiting toxicity, clinical laboratory tests, weight, electrocardiograms and physical examinations.

    Time frame: Part 1 and Part 2

  4. Assess the efficacy of the study drug in terms of incidence of complete remission (CR) and hematologic improvement (CRp).

    Time frame: Part 3

Secondary outcomes

  1. Assess the efficacy of the study drug in terms of incidence of CR and CRp.

    Time frame: Part 1 and Part 2

  2. Characterize the safety profile of the study drug in terms of adverse events, dose limiting toxicity, clinical laboratory tests, weight, electrocardiograms and physical examinations.

    Time frame: Part 3

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Phase 1/2 Study of ARRY-520 in Patients With Advanced Myeloid Leukemia

Important dates

Study start
2008
Primary completion
2010
Study completion
2010
First posted
Mar 17, 2008
Registry last updated
Feb 8, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.